Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines

PharmacoEconomics

Volumn 32, Issue 6, 2014, Pages 525-531

  Newall, A T ^a   Jit, M ^b,c   Hutubessy, R ^d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE; ROTAVIRUS VACCINE; VACCINE;

COST EFFECTIVENESS ANALYSIS; DECISION MAKING; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; INCOME; NOTE; PAPILLOMAVIRUS INFECTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITATIVE RESEARCH; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RISK FACTOR; ROTAVIRUS; THAILAND; VACCINATION; WART VIRUS; COST BENEFIT ANALYSIS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; ECONOMICS; MASS IMMUNIZATION; PUBLIC HEALTH; WORLD HEALTH ORGANIZATION;

COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; HUMANS; MASS VACCINATION; NATIONAL HEALTH PROGRAMS; PAPILLOMAVIRUS VACCINES; ROTAVIRUS VACCINES; VACCINES; WORLD HEALTH ORGANIZATION;

EID: 84902261172     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0162-x     Document Type: Note

References (34)

1. Drummond M, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
2. Bobadilla J-L, Cowley P, Musgrove P, et al. Design, content and financing of an essential national package of health services. Bull World Health Organ. 1994;72(4):653.
3. Tan-Torres Edejer T, Baltussen RM, Adam T, et al. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.
4. Hutubessy R, Chisholm D, Tan-Torres Edejer T, et al. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc. 2003;1:8.
5. WHO Commission on Macroeconomics and Health. Investing in health for economic development: report of the Commission on Macroeconomics and Health. Geneva: World Health Organization; 2001.
6. Shillcutt SD, Walker DG, Goodman CA, et al. Cost effectiveness in low-and middle-income countries: a review of the debates surrounding decision rules. PharmacoEconomics. 2009;27(11):903-17.
7. Williams A. What could be nicer than NICE?. London: Office of Health Economics; 2004.
8. Smith RD, Richardson J. Can we estimate the 'social' value of a QALY? Four core issues to resolve. Health Policy. 2005;74(1):77-84. (Pubitemid 41132574)
9. Torrance GW, Zipursky A. Cost-effectiveness of antepartum prevention of Rh immunization. Clin Perinatol. 1984;11(2):267-81. (Pubitemid 14051622)
10. Fesenfeld M, Hutubessy R, Jit M. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. Vaccine. 2013;31(37):3786-804.
11. Tu HAT, Woerdenbag HJ, Kane S, et al. Economic evaluations of rotavirus immunization for developing countries: a review of the literature. Expert Rev Vaccines. 2011;10(7):1037-51.
12. Vanni T, Mendes Luz P, Foss A, et al. Economic modelling assessment of the HPV quadrivalent vaccine in Brazil: a dynamic individual-based approach. Vaccine. 2012;30(32):4866-71.
13. Praditsitthikorn N, Teerawattananon Y, Tantivess S, et al. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand. PharmacoEconomics. 2011;29(9):781-806.
14. Sharma M, Ortendahl J, Van Der Ham E, et al. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand. BJOG. 2012;119(2):166-76.
15. Termrungruanglert W, Havanond P, Khemapech N, et al. Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries. Value Health. 2012;15(1 Suppl):S29-34.
16. Chotivitayatarakorn P, Chotivitayatarakorn P, Poovorawan Y. Cost-effectiveness of rotavirus vaccination as part of the national immunization program for Thai children. Southeast Asian J Trop Med Public Health. 2010;41(1):114-26.
17. Decision making and implementation of rotavirus vaccines. 2013; http://www.who.int/nuvi/rotavirus/decision-implementation/en/index1.html.
18. Decision making and implementation of human papillomavirus vaccines. 2013; http://www.who.int/nuvi/hpv/decision-implementation/en/.
19. US CPI inflation calculator. http://www.bls.gov/data/inflation- calculator.htm.
20. Burchett HED, Mounier-Jack S, Griffiths UK, et al. New vaccine adoption: qualitative study of national decision-making processes in seven low- and middle-income countries. Health Policy Plan. 2012;27(Suppl 2):ii5-16.
21. Singer ME. Developing nations special issue. PharmacoEconomics. 2009;27(11):887-9.
22. Burchett HED, Mounier-Jack S, Griffiths UK, et al. National decision-making on adopting new vaccines: a systematic review. Health Policy Plan. 2012;27(Suppl 2):ii62-76.
23. Harris AH, Hill SR, Chin G, et al. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. Med Decis Mak. 2008;28(5):713-22.
24. Muangchana C, Riewpaiboon A, Jiamsiri S, et al. Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand. Vaccine. 2012;30(18):2839-47.
25. Mirelman A, Mentzakis E, Kinter E, et al. Decision-making criteria among national policymakers in five countries: a discrete choice experiment eliciting relative preferences for equity and efficiency. Value Health. 2012;15(3):534-9.
26. Rose J, Hawthorn RL, Watts B, et al. Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. BMJ (Online). 2009;339(7724):787-91.
27. Paulden M, McCabe C, Karnon J. Achieving allocative efficiency in healthcare: nice in theory, not so NICE in practice? PharmacoEconomics. 2014;32:1-4.
28. Claxton KM, Soares M, Rice N, Spackman E, Hinde S, Devlin NS, Smith PC, Sculpher M. Methods for the estimation of the NICE cost effectiveness threshold. York: University of York; 2013.
29. Kim SY, Sweet S, Chang J, et al. Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden. BMC Infect Dis. 2011;11:174.
30. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. PharmacoEconomics. 2008;26(9):733-44.
31. Birch S, Gafni A. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold. J Health Serv Res Policy. 2006;11(1):46-51. (Pubitemid 43117113)
32. Ham C. Retracing the Oregon trail: the experience of rationing and the Oregon health plan. Br Med J. 1998;316(7149):1965-9. (Pubitemid 28287149)
33. Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518-28. (Pubitemid 39390832)
34. Briggs AH, Gray AM. Handling uncertainty in economic evaluations of healthcare interventions. Br Med J. 1999;319(7210):635-8. (Pubitemid 29414568)